# TCR therapy (T-cell receptor engineered T cells)

Patient T cells are engineered with a high-affinity T-cell receptor (TCR) that recognises a peptide-MHC complex inside a solid-tumour cell — an approved one-time therapy reaching tumour targets CAR-T cannot, led by Adaptimmune's Tecelra and Immunocore's Kimmtrak, with a deeper pipeline advancing MAGE-A4, NY-ESO-1, gp100 and PRAME targets.

Source: https://en.bioecon.ru/technology/tcr-therapy/
Updated: 2026-08-18



## Overview and value chain

Markers: [EC: ATMP Regulation (EC No 1394/2007) + FDA cell-therapy guidance | OECD: Bio-pharma | Regulator: FDA (USA), EMA (European Union), NMPA (China)]

TCR therapy engineers a patient's T cells with a high-affinity T-cell receptor (TCR) that recognises an intracellular tumour peptide presented on HLA — a target class that CAR-T (which sees surface antigens) cannot reach. Adaptimmune's Tecelra (afamitresgene autoleucel) was the first TCR-T approved, targeting MAGE-A4 in synovial sarcoma, and Immunocore's Kimmtrak (tebentafusp), a soluble TCR-bispecific against gp100, was shown in April 2026 to double the likelihood of being alive at five years in metastatic uveal melanoma. Lyell Immunopharma reported a June 2026 safety update on LYL273 in relapsed solid tumours, TScan Therapeutics is building a TCR-T discovery and treatment platform (Nasdaq: TCRX, Q1 2026), and Medigene's MDG1015 is a first-in-class, third-generation TCR construct. The field is the engineered-T-cell answer to solid tumours.

The key directions of TCR therapy are:
1. **Autologous TCR-T cell therapy (TCR-T):** patient T cells transduced with an affinity-enhanced TCR against an intracellular peptide-MHC target — Adaptimmune (Tecelra, MAGE-A4), Lyell (LYL273), TScan, Medigene (MDG1015).
2. **Soluble TCR bispecifics (TCR Bispecific):** a fused TCR-anti-CD3 molecule that recruits polyclonal T cells to a tumour peptide-MHC — Immunocore (Kimmtrak/tebentafusp, gp100).
3. **TCR discovery and target selection (TCR Discovery):** high-throughput identification of tumour-specific peptide-MHC targets (MAGE-A4, NY-ESO-1, gp100, PRAME) and of high-affinity, HLA-restricted TCRs (e.g. HLA-A*02:01).
4. **Solid-tumour durability and manufacturing (Solid Tumour):** epigenetic reprogramming to resist T-cell exhaustion (Lyell) and point-of-care manufacturing to shorten vein-to-vein time.

### Sectoral value chain

```
[tumour peptide-MHC target] ──> [high-affinity TCR isolation + lentiviral vector] ──> [engineered TCR-T product]
                                              │
                                     (lymphodepletion conditioning)
                                              │
                                              ▼
[solid-tumour response] <─── [TCR-T infusion + immune management] <─────┘
```

### Value chain levels

| Level | Description | Key inputs/outputs |
|:---|:---|:---|
| **Antigen & TCR Discovery** | identify tumour peptide-MHC and isolate a high-affinity HLA-restricted TCR | **In:** genomics, assay.<br>**Out:** TCR clone. |
| **TCR Engineering** | clone TCR alpha/beta, affinity-mature, build lentiviral vector with chain-pairing modification | **In:** TCR sequence.<br>**Out:** vector. |
| **Cell Manufacturing** | transduce patient T cells, expand and release under GMP | **In:** patient T cells, vector.<br>**Out:** TCR-T product. |
| **Lymphodepletion** | patient chemotherapy conditioning to enable TCR-T expansion | **In:** patient, chemo.<br>**Out:** conditioned host. |
| **Infusion & Monitoring** | TCR-T infusion and management of immune toxicity | **In:** product, supportive care.<br>**Out:** response. |
| **Follow-up & PV** | long-term persistence, safety and pharmacovigilance | **In:** follow-up data.<br>**Out:** safety record. |

Cross-cutting technologies of the sector:
- **HLA-restricted peptide-MHC targeting (MHC Restriction):** TCRs recognise intracellular peptides presented on HLA (e.g. HLA-A*02:01), which is what lets TCR therapy reach solid-tumour targets CAR-T cannot, but also ties each product to a patient's HLA type.
- **Lentiviral TCR delivery (Lentiviral Vector):** TCR alpha and beta chains are delivered via integrating lentiviral vector, with engineered cysteine modifications to enforce correct pairing and avoid mis-pairing with the endogenous TCR.
- **Soluble TCR bispecifics (TCR Bispecific):** Immunocore's Kimmtrak fuses an affinity-enhanced TCR to an anti-CD3 scFv, turning the TCR into an off-the-shelf drug that recruits polyclonal T cells.

---

## US

The US hosts Lyell Immunopharma and TScan Therapeutics, and the FDA approved the first TCR-T product.

### Lyell, TScan, FDA
- **Lyell Immunopharma (Nasdaq: LYEL):** a late-stage clinical company advancing next-generation chimeric antigen receptor and TCR-T cell therapies, with a June 2026 safety update on LYL273 in relapsed solid tumours; its epigenetic reprogramming technology addresses T-cell exhaustion, the central obstacle in solid-tumour cell therapy.
- **TScan Therapeutics (Nasdaq: TCRX):** a clinical-stage biotechnology company building a TCR discovery and TCR-T treatment platform, reporting first-quarter 2026 financials in May 2026; it identifies tumour-specific targets via T-cell receptor sequencing.
- **FDA framework:** TCR-T products are approved as biologics / ATMPs with risk evaluation and mitigation strategies; the first TCR-T approval (Tecelra, 2024) established the regulatory pathway for HLA-restricted personalised cell therapy.

---

## CN

China's TCR-T field is emerging and largely pre-commercial, with academic and early-stage biotech activity rather than a marketed product.

### emerging TCR-T, NMPA, academic
- **Emerging pre-commercial field:** enrichment returned blog and academic coverage rather than a source-confirmed commercial Chinese TCR-T product, so the CN block is treated qualitatively; domestic activity is early-stage.
- **NMPA pathway:** TCR-T candidates enter clinical development under the NMPA cell-therapy framework, behind the US/EU leaders but within China's broader cell-therapy investment wave.
- **Solid-tumour rationale:** China's large solid-tumour burden underpins interest in TCR-T, which — unlike CAR-T — can target intracellular tumour antigens presented on HLA.

---

## EU

Europe is the origin of both approved TCR products — Adaptimmune and Immunocore are UK-based — plus Medigene's TCR pipeline.

### Adaptimmune, Immunocore, Medigene, EMA
- **Adaptimmune (United Kingdom):** its TCR-T product Tecelra (afamitresgene autoleucel) targets MAGE-A4 in synovial sarcoma and was the first engineered-TCR cell therapy approved, anchoring the autologous TCR-T class alongside pipeline assets lete-cel (NY-ESO-1) and other MAGE-A4/PRAME programmes.
- **Immunocore (United Kingdom):** Kimmtrak (tebentafusp), a soluble gp100 TCR-anti-CD3 bispecific for HLA-A*02:01+ metastatic uveal melanoma, was reported in April 2026 to double the likelihood of being alive at five years — the first TCR-based bispecific approved.
- **Medigene (Germany):** MDG1015 is a first-in-class, third-generation TCR construct, with the company's broader pipeline (MDG3020, MDG3010) extending its TCR platform.
- **EMA framework:** TCR therapies are advanced therapy medicinal products centrally authorised by the European Medicines Agency under Regulation (EC) No 1394/2007.

---

## Leading companies and research institutes

| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|:---|:---|:---|:---|:---|
| **Adaptimmune** | 🇬🇧 United Kingdom | *Tecelra (afamitresgene)* | TCR-T, MAGE-A4 sarcoma | commercial |
| **Immunocore** | 🇬🇧 United Kingdom | *Kimmtrak (tebentafusp)* | TCR bispecific, gp100 | commercial |
| **Lyell Immunopharma** | 🇺🇸 USA | *LYL273 pipeline* | TCR-T, epigenetic reprogramming | operating |
| **TScan Therapeutics** | 🇺🇸 USA | *TCR discovery platform* | TCR-T, TCRX | operating |
| **Medigene** | 🇩🇪 Germany | *MDG1015 3rd-gen TCR* | TCR-T platform | operating |

---

## Tech stack and innovations

The stack pairs high-affinity TCR discovery with chain-engineered lentiviral delivery, autologous GMP manufacturing, and — for the bispecific variant — a soluble TCR that recruits polyclonal T cells.

1. **Autologous TCR-T (TCR-T):**
   - Adaptimmune's Tecelra (afamitresgene autoleucel) is the first approved TCR-T, targeting MAGE-A4 in synovial sarcoma; Lyell's LYL273 (June 2026 safety update) and Medigene's MDG1015 (third-generation TCR) extend the autologous class.
   - Lyell's epigenetic reprogramming directly addresses T-cell exhaustion, the central reason engineered T cells fail in solid tumours.
2. **Soluble TCR bispecifics (TCR Bispecific):**
   - Immunocore's Kimmtrak (tebentafusp) fuses an affinity-enhanced gp100 TCR to an anti-CD3 scFv, and was shown in April 2026 to double five-year survival in HLA-A*02:01+ metastatic uveal melanoma.
   - The bispecific format converts the TCR from a cell-bound receptor into an off-the-shelf drug that redirects the patient's existing T cells.
3. **TCR discovery and targeting (TCR Discovery):**
   - TScan Therapeutics uses T-cell receptor sequencing to identify tumour-specific peptide-MHC targets and the TCRs that recognise them, feeding a pipeline across MAGE-A4, NY-ESO-1, gp100 and PRAME.
   - HLA restriction (e.g. HLA-A*02:01) is the defining constraint — and the opportunity — that lets TCR therapy reach intracellular tumour antigens.

---

## Value chains and production pipelines

### Industrial pipeline of an autologous TCR-T product (ATMP Regulation, HLA-restricted)

```
┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Antigen & TCR          │ ───> │ 2. TCR engineering &      │
│    discovery              │      │    vector production      │
└───────────────────────────┘      └───────────────────────────┘
                                                   │
                                                   ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Lymphodepletion        │ <─── │ 3. Autologous cell        │
│                           │      │    manufacturing          │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Infusion & monitoring  │ ───> │ 6. Follow-up & PV         │
└───────────────────────────┘      └───────────────────────────┘
```

#### Stage 1: Antigen and TCR discovery
Tumour-specific intracellular antigens (MAGE-A4, NY-ESO-1, gp100, PRAME) are identified, their peptide-MHC presentation characterised, and high-affinity, HLA-restricted TCRs (e.g. HLA-A*02:01) isolated by high-throughput screening (TScan platform).

#### Stage 2: TCR engineering and vector production
The selected TCR alpha and beta chains are cloned, affinity-matured and engineered with cysteine modifications to enforce correct pairing and avoid mis-pairing with the endogenous TCR, then packaged in a lentiviral vector.

#### Stage 3: Autologous cell manufacturing
The patient's T cells are transduced with the TCR lentiviral vector, expanded in closed GMP systems, and released as a cryopreserved TCR-T product, tied to the patient's HLA type.

#### Stage 4: Lymphodepletion
The patient receives lymphodepleting chemotherapy to create immunological space for TCR-T expansion and persistence in the solid-tumour microenvironment.

#### Stage 5: Infusion and monitoring
The TCR-T product is re-infused and the patient is monitored for immune toxicity (cytokine release, on-target/off-tumour effects against normal MAGE-A4-positive tissues) and early response.

#### Stage 6: Follow-up and pharmacovigilance
Long-term follow-up tracks TCR-T persistence, durability of solid-tumour response and late toxicities, feeding the pharmacovigilance record that supports the still-young TCR-T class.